Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach
© Karelina et al.; licensee BioMed Central Ltd. 2012
Received: 20 August 2012
Accepted: 18 October 2012
Published: 12 November 2012
5-lipoxygenase (5-LO) is a key enzyme in the synthesis of leukotrienes and 5-Oxo-6E,8Z,11Z,14Z-eicosatetraenoic acid (oxoETE). These inflammatory signaling molecules play a role in the pathology of asthma and so 5-LO inhibition is a promising target for asthma therapy. The 5-LO redox inhibitor zileuton (Zyflo IR/CR®) is currently marketed for the treatment of asthma in adults and children, but widespread use of zileuton is limited by its efficacy/safety profile, potentially related to its redox characteristics. Thus, a quantitative, mechanistic description of its functioning may be useful for development of improved anti-inflammatory targeting this mechanism.
A mathematical model describing the operation of 5-LO, phospholipase A2, glutathione peroxidase and 5-hydroxyeicosanoid dehydrogenase was developed. The catalytic cycles of the enzymes were reconstructed and kinetic parameters estimated on the basis of available experimental data. The final model describes each stage of cys-leukotriene biosynthesis and the reactions involved in oxoETE production. Regulation of these processes by substrates (phospholipid concentration) and intracellular redox state (concentrations of reduced glutathione, glutathione (GSH), and lipid peroxide) were taken into account. The model enabled us to reveal differences between redox and non-redox 5-LO inhibitors under conditions of oxidative stress. Despite both redox and non-redox inhibitors suppressing leukotriene A4 (LTA4) synthesis, redox inhibitors are predicted to increase oxoETE production, thus compromising efficacy. This phenomena can be explained in terms of the pseudo-peroxidase activity of 5-LO and the ability of lipid peroxides to transform 5-LO into its active form even in the presence of redox inhibitors.
The mathematical model developed described quantitatively different mechanisms of 5-LO inhibition and simulations revealed differences between the potential therapeutic outcomes for these mechanisms.
Leukotrienes are key inflammatory mediators associated with pathological states of inflammation in diseases such as asthma and allergic rhinitis and play a pivotal role in normal host defense. They have been shown to promote leukocyte chemotaxis and activation, vascular tone and permeability, smooth muscle contractility and immune function. 5-lipoxygenase (5-LO) is the key enzyme of leukotriene biosynthesis and so is a promising target for drug development[2, 3].
5-LO activity is controlled by the intracellular Ca2+ concentration and the cellular redox state[4–6, 12, 13]. The redox state modulates activity via the iron (Fe) atom located in the catalytic site of the enzyme. HP and other lipid peroxides are able to oxidize the Fe atom from Fe2+ (ferrous state) to the active Fe3+ (ferric state). Consistent with this the addition of glutathione peroxidase (GPx) inhibits formation of products of 5-LO catalyzed reactions in vitro. Similar to other lipoxygenases, 5-LO also demonstrates redox state dependent hydroperoxidase activity: ferrous 5-LO reacts with lipid-hydroperoxide to form ferric 5-LO, an oxygen-centered lipid radical and hydroxide ion. Additionally, 5-LO activity, in the presence of Ca2+, is increased by structural stabilization via ATP (adenosine-5’-triphosphate) without ATP hydrolysis, microsomal membranes or phosphatidylcholine vesicles (PtdCho). Mitogen activated protein MAP kinase cascade activity, nuclear import and export of 5-LO, interaction with coactosin-like protein (CLP), 5-LO activating protein (FLAP) and phosphorylation of the enzyme by protein kinase A, resulting in suppression of 5-LO activity, also have been reported to modulate it’s activity.
Most of the known inhibitors of the 5-LO act on the basis of a redox-mechanism or by chelation of the Fe atom of 5-LO. Redox inhibitors reduce the Fe atom from active ferric state to the inactive ferrous state. The complexity of 5-LO regulation and the multiple reaction paths suggests that redox and non-redox inhibitors may have qualitatively and quantitatively different effects on the products of 5-LO catalyzed reactions.
Zileuton (Z, N-(l-benzo(b)thien-2-ylethyl)-N-hydroxyurea or Zyflo IR/CR®), is a redox inhibitor of 5-LO currently approved for the daily treatment of asthma in adults and children. Zileuton has a sub-optimal pharmacokinetic and pharmacodynamic profile resulting in a high total daily dose (2400mg) and frequent dosing (4 times a day [q.i.d] for Zyflo IR® and twice a day [b.i.d] for Zyflo CR®), plus a potential for hepatotoxicity. Therefore, the development of a medicine with more convenient dosing regimen may maximise the benefits of inhibiting the leukotriene pathway and provide efficacy superior to that obtained with zileuton. PF-4191834, 4-(3-(4-(1-methyl-1H-pyrazol-5-yl)phenylthio)phenyl)-tetrahydro-2H-pyran-4-carboxamide (PF), is a novel non-iron chelating, non-redox, 5-LO inhibitor under investigation for the treatment of various inflammatory conditions. The presence of significant data in the public domain for zileuton and PF suggested that development of a mathematical model would allow insight into the potential differential effects of non-redox and redox inhibitors. To characterize these potential effects it was necessary to attempt to capture the key properties of the entire pathway and its interactions in inflammatory states Therefore, a detailed mathematical model, describing the processes of 5-LO mediated catalysis regulation (self-inactivation, effect of redox state of the medium) was developed.
Several mathematical models of 5-LO have already been reported, for example a model describing the inhibition of lipoxygenase activity by one of the substrates of the enzyme, AA, by Aharony et al.. In this model, 5-LO is able to bind 2 molecules of AA simultaneously (one molecule in the catalytic site and other molecule in the additional regulatory site) which renders the enzyme catalytically inactive. However, LTA synthesis and the pseudo-peroxidase reaction have not been taken into account in this model. An alternative model of reticulocyte lipoxygenase was developed with 9,12(Z,Z)-octadecadienoic acid (linoleic acid) as substrate. This model did take into account both the activation of the enzyme by product, hydroperoxy derivative of fatty acid, and inhibition of 5-LO with substrate, polienoic fatty acid. However, the substrate inhibition was described in terms of a competitive mechanism, binding to inactive form of 5-LO thus preventing its activation, and the LTA4 synthase activity of the enzyme was not captured. Additionally, none of the models describe the reversible inactivation of 5-LO with HT and irreversible inactivation with LTA4.
The rate laws for lipoxygenase and LTA4 synthase reactions were derived by Yang et al., where the influence of various inhibitors of 5-LO and cyclooxygenase on AA metabolism were determined. These rate equations take into account the inhibition of 5-LO activity by LTA4, HP and HT. However, the inhibition with LTA4 was also described as reversible and the substrate inhibition, product activation and pseudo-peroxidase activity of 5-LO were not taken into account.
Therefore, an opportunity exists to develop a more detailed model of 5-LO activity which describes all the activities of the enzyme and their regulation by substrates and products. The main purpose of this paper is to summarize the development of a detailed mathematical model of 5-LO operation, its application to describe the production of LTA4 and oxoETE, and to study the differences between redox and non-redox inhibitors. The “LOS (Leukotriene-OxoeETE-Synthesis) model” (Figure1) includes four enzymes: 5-LO, cytosolic phospholipase A2 (cPLA2), GPx and HEDH and describes the major interactions between the components of the system (for example, the influence of glutathione concentration on 5-LO activity). We used the “LOS model” to predict the dose-responses of various inflammatory mediators to redox and non-redox inhibitors and provide a mechanistic explanation for the differences between them.
The “LOS model” describing LTA4 and oxoETE production in leukocytes includes reactions catalyzed by 5-LO, cPLA2, GPx, HEDH and degradation of HT, oxoETE and LTA4. Since all leukotrienes are synthesized from LTA4, analysis of 5-LO catalyzed LTA4 production was deemed sufficient to evaluate the impact of 5-LO on leukotriene production. Catalytic cycles for each of the enzymes were constructed and rate equations describing the dependence of reaction rate on concentrations of substrates, products and effectors were derived utilizing literature data.
The kinetic model of 5-LO
Known experimental data and hypotheses used for the model development
AA inhibits 5-LO activity in lipoxygenase reaction at high concentrations (substrate inhibition) .
LTA4 can be synthesized from exogenous HP .
5-LO is self-inactivating . Glutathione peroxidase and glutathione protect the enzyme from inactivation and lipid peroxides eliminate the protective effect of glutathione.
HT is a reversible inhibitor of 5-LO .
LTA4 can inactivate 5-LO irreversibly .
The Fe atom in the catalytic site exists in two possible states Fe2+ and Fe3+. Fe3+ is the catalytically active state. Transition between Fe2+ and Fe3+ states proceeds via oxidation by lipid peroxides, including HP . Reduction from Fe3+ to Fe2+ state can be mediated by redox inhibitors (zileuton).
Oxidation of the enzyme (Fe2+ → Fe3+ transition) is influenced by Ca2+ ions .
Endogenously generated 5-HP is the preferential substrate for the 5-LO mediated LTA-synthase reaction .
ATP and membrane binding are necessary for 5-LO activation .
There are two sites for AA binding: the catalytic site and regulatory site. HT is a competitive inhibitor at the catalytic site.
Binding of AA to the regulatory site results in formation of dead-end complexes with 5-LO.
Binding of AA and HT to the catalytic site are fast reactions in comparison to product formation.
Oxidation and reduction of 5-LO (transition between Fe2+ and Fe3+) can result from (i) interaction with lipid peroxides or (ii) “spontaneously” (by means of interaction with oxidative or reducing factors: O2, H2O2, thiol groups etc.).
Ca2+ is able to bind to the catalytic site, but it influences only oxidation and reduction reactions, thus kinetic parameters of other reactions of catalytic cycle remain unchanged.
Binding of Ca2+ and redox-inhibitors (Z) are fast reactions in comparison to the other reactions of the catalytic cycle.
Redox inhibitors are only able to bind to the catalytic site of 5-LO and only when it is not occupied with other factors.
The binding of redox inhibitors to the catalytic site blocks the binding of other factors .
The regulatory site is able to bind AA only if following conditions are fulfilled: (i) 5-LO is in Fe3+ state and (ii) the enzyme is not bound to a redox-inhibitor.
The oxygenase, pseudoperoxydase and LTA4 synthase activities of 5-LO were simplified by not describing electron transfer and oxygen binding. Instead, it was assumed that the oxygen concentration is in saturation, i.e., it is not a parameter of the model.
To decrease the number of unknown parameters in our model we have assumed that binding of AA to the regulatory site of 5-LO does not influence the binding of AA, HP and HT to the catalytic site (see Additional file 1: Appendix 1).
Interaction with MAP kinases, FLAP, CLP and transport of 5-LO to the nucleus have not been taken into account in the model.
Catalytic cycle of 5-LO
Transitions between the states are described in accordance to mass action law and can be either reversible (for example, binding AA to catalytic site) or irreversible (for example, the LTA-synthase reaction). Moreover, these processes can be either relatively fast or slow depending on the values of rate constants obtained from experimental data fitting. This grouping of all processes into two sets (fast and slow processes) allowed us to reduce the initial complexity of the catalytic cycle and derive rate equations describing the operation of 5-LO according to the methods described in.
Since 5-LO undergoes irreversible inactivation, the concentration of active enzyme tends to zero with time and, consequently, all enzyme catalyzed reactions become equal to zero. In vivo, regulatory mechanisms control intracellular 5-LO production de novo. To obtain non-zero steady state concentrations of 5-LO states and, consequently, to derive the rate equations describing the activities of 5-LO, we did not consider self-inactivation of the enzyme and have not taken into account processes responsible for 5-LO production de novo. Under these assumptions the total concentration of active enzyme (F a ) is equal to total enzyme concentration and F a is a parameter of the model. Additionally, identification of model parameters using in vitro experimental data was performed on the basis of a model which takes into account self-inactivation of 5-LO with time (see Additional file1: Appendix 1.5). Under these conditions F a represents the sum of active states of 5-LO and changes with time. All rate equations were derived on the basis of the quasi-steady state approach.
The kinetic model of phospholipase A2
The kinetic model of glutathione peroxidase
The kinetic model of 5-hydroxyeicosanoid dehydrogenase
The LTA4 and oxoETE synthesis model (“LOS model”)
To build the “LOS model” we utilized the rate equations describing the activities of 5-LO, phospholipase A2, glutathione peroxidase and 5-hydroxyeicosanoid dehydrogenase as given above. The kinetic scheme of the “LOS model” is shown in Figure1. In accordance with the scheme, AA binding to 5-LO is converted to HP via the lipoxygenase reaction. As a result a complex of 5-LO and HP is formed. HP can be either released from the complex (V HPsyn 5LO) or used to form LTA4 via the LTA4-synthase reaction V LTAsyn 5LO. Additionally, LTA4 can be produced from free HP in the absence of AA (see sequence of reversible reaction V HPsyn 5LO and irreversible reaction V LTAsyn 5LO). To present all these process correctly the intermediate state of the enzyme (Ca)F HP (AA) (complex 5-LO with HP) was added to the kinetic scheme. The concentration of the state (Ca)F HP (AA) is not a variable of the model, i.e. there are no differential equations describing the time dynamics of (Ca)F HP (AA). However, in accordance with the quasi-steady state approach chosen to describe 5-LO operation in the “LOS model” (and, consequently, applied to derive rate equations of various 5-LO activities) concentration of state (Ca)F HP (AA) is expressed in terms of variables of the “LOS model” (see Additional file1: Appendix 1).
To avoid unlimited accumulation of metabolites resulting from constant influx of AA we have introduced processes of degradation of HT, oxoETE and LTA4 (V HTd , V LTAd and V oxoETEd ) in the model. The reaction rates of these processes are described in accordance with mass action law (Additional file1: Appendix 5). Additionally, concentrations of PL, lipid peroxide LOOH and its reduced product LOH, reduced (GSH) and oxidized (GSSG) glutathione, and reduced and oxidized forms of NADPH are considered as parameters of the model, i.e., do not change with time. The values for the intracellular concentrations of GSH, GSSG, NADPH and NADP were taken from the following sources[30–34]. The concentration of LOOH has either been chosen on the basis of known experimental conditions or has been varied to describe various oxidative states of the cells.
Description of the parameters of the “LOS model” and experimental data used for their identification
Here, n is the total number of experimental points, is the experimentally measured value of the variable or reaction rate, v i is the value of the variable or reaction rate calculated based on the model at a point corresponding to the experimental ones.
Given the complexity of the model, simultaneous identification of parameter estimates would be challenging. Therefore, parameter identification was performed individually for each enzyme by fitting to literature data sets pertinent to the specific enzyme. For example, the parameters of 5-LO were identified via fitting of the 5-LO model against more than 10 experimentally measured curves (76 experimental points)[22, 24–26, 37, 38], 4 unknown parameters of GPx were identified on the basis of 12 experimentally measured points and the parameters of HEDH have been fitted against 47 experimental points.
Results and discussion
Modeling of 5-LO kinetics
Kinetic parameters of enzyme catalytic cycles
V max PLA 2
K m PLA 2 _ APC
K Ca PLA 2
K 2 Ca
K 2 Ca
K AA i
K GSSG gpx
k cat gpx
K NADP hedh
K NADPH hedh
K oxoETE hedh
K HT hedh
k 1 hedh
k 2 hedh
k - 1 hedh
k - 2 hedh
Modeling of the response to redox and non-redox inhibitors of 5-LO
We applied the “LOS model” to study the influences of redox and non-redox inhibitors on the operation of 5-LO. Inhibitor PF has been profiled in stimulated human whole blood (HWB) against several relevant human targets including 5-LO, 12-LOX, 15-LO and COX enzymes. The compound completely inhibited the synthesis of the 5-LO products (HT, oxoETE, LTB4 and LTE4) with estimated IC50s between 100 and 190 nM. These data demonstrate that the non-redox inhibitor PF is 6–10 times more potent than zileuton.
The mechanism of 5-LO inhibition by the redox and non-redox inhibitors has been modeled under LTA4 steady-state concentration (Additional file1: Appendix 1). Parameter values describing the kinetic properties of redox and non-redox 5-LO inhibitors were chosen in such a way to provide satisfactory coincidence between the IC50 and IC80 measured experimentally and those calculated by the “LOS model”.
Thus, comparison of the model simulations to two sets of experimental data which were not used in parameter identification enabled us to conclude that our model adequately described the influence of inhibitors on the system behavior.
Difference between redox and non-redox inhibitors
where LTA 4 st inh , oxoETE st inh ,are steady-state concentrations of LTA4 and oxoETE at a specified inhibitor concentration LTA 4 st inh = 0, oxoETE st inh = 0 are steady-state concentrations of LTA4 and oxoETE in the absence of inhibitor.
Potency of 5-LO Inhibitors in “LOS” model at different peroxide concentrations
Peroxide concentration (μM)
IC50 for inhibition by Zileuton (nM)
IC50 for inhibition by PF-4191834(nM)
Potency of 5-LO inhibitors in whole blood from control (Normal) and asthmatic human volunteer
850 ± 220
2270 ± 710
1080 ± 220
2520 ± 1010
120 ± 10
300 ± 20
180 ± 20
390 ± 50
Assuming a level of LOOH in healthy controls of 5 ÂµM (see Figures11–12, (dashed lines)) we have found that curves describing level of inhibition of LTA4 and oxoETE show a similar tendency but in case of inhibition with zileuton a new feature was observed. The increase in LOOH level from 0 to 5 ÂµM was accompanied by a decrease in zileuton potency for inhibition of oxoETE synthesis (see Figure12, dashed line) in comparison with its potency to inhibit LTA4 synthesis (IC50LTA4<IC50oxoETE). This effect is more pronounced when setting the [LOOH] equal to 10 ÂµM (approximating that of asthmatic patients, Figures11–12, dotted lines). To further illustrate this effect we simulated the impact of a supra-physiological LOOH concentration of 100 ÂµM on the inhibitory properties of compounds (dash-dot lines in Figures11b and12b).
Discussion of redox-inhibitor properties at high oxidative stress
Zileuton donates an electron to the active (Fe3+) state of 5-LO to form the inactive ferrous (Fe2+) state and a zileuton radical (see reaction r7 in Figure3). The zileuton radical is eliminated without subsequent reduction to zileuton. To activate 5-LO it is necessary to oxidize the inactive ferrous (2+) state, i.e. an electron donated to an acceptor such as HP or LOOH. Therefore, under conditions of low LOOH only HP is able to oxidize 5-LO. If zileuton is applied, 5-LO is converted to the inactive ferrous state, the rate of HP synthesis decreases and, as a consequence, the enzyme is completely inhibited because of lack of its oxidation. In the absence of other sources of lipid peroxides and HP, 5-LO is completely inhibited by zileuton.
Under conditions of high LOOH, the transformation of ferrous 5-LO state into ferric state can proceed in two possible ways: either via HP or LOOH reduction (see reaction r 6 in Figure3). When zileuton is applied, the concentration of ferrous state of 5-LO increases. However, high level of LOOH may compensate for the lack of HP in the pseudo-peroxidase reaction that leads to maintenance of level of the active 5-LO state and, as a consequence, the lipoxygenase reaction occurs. Under these conditions the rate of pseudo-peroxidase reaction increases and both HP and LOOH are reduced in this reaction converting 5-LO into active ferric state. As a consequence of increased HP consumption in the pseudo-peroxidase reaction, its concentration decreases, leading to a decrease in LTA4 production. At the same time increases in HT concentration produced in the pseudo-peroxidase reaction leads to further increase in oxoETE production.
Both redox and non-redox inhibitors of 5-LO decrease LTA4 production independently of lipid peroxide level.
Non-redox inhibitors of 5-LO decrease HT production (and, consequently, 5-oxoETE) independently of lipid peroxide level.
The effect of redox inhibitors on oxoETE production strongly depends on LOOH level;
Redox inhibition of 5-LO under condition of high LOOH switches 5-LO from LTA4 production to HT (and, consequently, oxoETE) production.
OxoETE is one of the key inflammatory mediators and the results of our work presented in the paper have demonstrated that under certain conditions redox inhibitors can lead to a non-intuitive increase in oxoETE synthesis. Together with the PK disadvantages of zileuton this observation supports the further investigation of non-redox inhibitors as possible drugs against asthma.
5(S)-Hydroperoxy-6,8,1l,14- (E,Z,Z,Z)-eicosatetraenoic acid
Glutathione peroxidase 1
Zileuton or N-(l-benzo(b)thien-2-ylethyl)-N-hydroxyurea), Zyflo IR/CR®
all other lipid peroxides except HP, which can be consumed by 5-LO
products of pseudoperoxydase reactions with lipid peroxides except HP.
We would like to thank Jaime L. Masferrer for discussion of our results and Nail Gizzatkulov for help with calculations.
- Hammarstrom S: Leukotrienes. Ann Rev Biochem. 1983, 52: 355-77. 10.1146/annurev.bi.52.070183.002035.View Article
- Batt DG: 5-lipoxygenase inhibitors and their anti-inflammatory activities. Prog Med Chem. 1992, 29: 1-63.View Article
- Falgueyret J-P, Hutchinson JH, Riendau D: Criteria for the identification of non-redox inhibitors of 5-lipoxygenase. Biochem Pharmacol. 1993, 45: 978-981. 10.1016/0006-2952(93)90185-Y.View Article
- Ford-Hutchinson AW, Gresser M, Young RN: 5-lipoxygenase. Ann Rev Biochem. 1994, 63: 383-417. 10.1146/annurev.bi.63.070194.002123.View Article
- Werz O: 5-Lipoxygenase: cellular biology and molecular pharmacology. Curr Drug Targets Inflamm Allergy. 2002, 1: 23-44. 10.2174/1568010023344959.View Article
- Rådmark O: Arachidonate 5-lipoxygenase. Prostaglandins Other Lipid Mediat. 2002, 68–69: 211-234.View Article
- Martínez JI, García RD, Galarza AM: The kinetic mechanism of glutathione peroxidase from human platelets. Thromb Res. 1982, 27 (2): 197-203. 10.1016/0049-3848(82)90199-2.View Article
- Chiu DT, Stults FH, Tappel AL: Purification and properties of rat lung soluble glutathione peroxidase. Biochim Biophys Acta. 1976, 445: 558-66. 10.1016/0005-2744(76)90110-8.View Article
- Erlemann KR, Cossette C, Grant GE, Lee GJ, Patel P, Rokach J, Powell WS: Regulation of 5-hydroxyeicosanoid dehydrogenase activity in monocytic cells. Biochem J. 2007, 403: 157-65. 10.1042/BJ20061617.View Article
- Powell WS, Rokach J: Biochemistry, biology and chemistry of the 5-lipoxygenase product 5-oxo-ETE. Prog Lipid Res. 2005, 44: 154-83. 10.1016/j.plipres.2005.04.002.View Article
- Powell WS, Chung D, Gravel S: 5-Oxo-6,8,11,14-eicosatetraenoic acid is a potent stimulator of human eosinophil migration. J Immunol. 1995, 154: 4123-32.
- Radmark O, Werz O, Steinhilber D, Samuelsson B: 5-Lipoxygenase: regulation of expression and enzyme activity. Trends Biochem Sci. 2007, 32: 332-341. 10.1016/j.tibs.2007.06.002.View Article
- Radmark O, Samuelsson B: Regulation of 5-lipoxygenase enzyme activity. Biochem Biophys Res Commun. 2005, 338: 102-110. 10.1016/j.bbrc.2005.08.013.View Article
- Riendeau D, Falgueyret JP, Guay J, Ueda N, Yamamoto S: Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction. Biochem J. 1991, 274: 287-92.View Article
- Awni WM, Locke C, Dube LM, Cavanaugh JH: Evaluation of the diurnal variation in the pharmacokinetics of zileuton in healthy volunteers. J Clin Pharmacol. 1997, 37: 388-View Article
- Awni WM, Braeckman RA, Granneman GR, Witt G, Dubé LM: Pharmacokinetics and pharmacodynamics of zileuton after oral administration of single and multiple dose regimens of zileuton 600 mg in healthy volunteers. Clin Pharmacokinet. 1995, 29: 22-3. 10.2165/00003088-199500292-00005.View Article
- Joshi EM, Heasley BH, Chordia MD, Macdonald TL: In vitro metabolism of 2-acetylbenzothiophene: relevance to zileuton hepatotoxicity. Chem Res Toxicol. 2004, 17: 137-43. 10.1021/tx0341409.View Article
- Masferrer JL, Zweifel BS, Hardy M, Anderson GD, Dufield D, Cortes-Burgos L, Pufahl RA, Graneto M: Pharmacology of 4-(3-(4-(1-methyl-1H-pyrazol-5-yl) phenylthio) phenyl)-tetrahydro-2H-pyran-4-carboxamide (PF-4191834), a Novel Selective, non-redox, 5-Lipoxygenase Inhibitor Effective in Inflammation and Pain. J Pharmacol Exp Ther. 2010, 334: 294-301. 10.1124/jpet.110.166967.View Article
- Aharony D, Ross L, Stein RL: Kinetic mechanism of guinea Pig neutrophil 5-lipoxygenase. J Biol Chem. 1986, 261: 11512-11519.
- Ludwig P, Holzhutter H-G, Colosimo A, Silvestrini MC, Schewe T, Rapoport SM: A kinetic model for lipoxygenases based on experimental data with the lipoxygenase of reticulocytes. Eur J Biochem. 1987, 168: 325-337. 10.1111/j.1432-1033.1987.tb13424.x.View Article
- Aharony D, Redkar-Brown DG, Hubbs SJ, Stein RL: Kinetic studies on the inactivation of 5-lipoxygenase by 5(S)-hydroperoxyeicosatetraenoic acid. Prostaglandins. 1987, 33: 85-100. 10.1016/0090-6980(87)90307-8.View Article
- Lepley RA, Fitzpatrick FA: Irreversible inactivation of 5-lipoxygenase by leukotriene A4. Characterization of product inactivation with purified enzyme and intact leukocytes. J Biol Chem. 1994, 269: 2627-2631.
- Yang K, Ma W, Liang H, Ouyang Q, Tang C, Lai L: Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput Biol. 2007, 3: e55-10.1371/journal.pcbi.0030055.View Article
- Pande AH, Moe D, Nemec KN, Qin S, Tan S, Tatulian SA: Modulation of human 5-lipoxygenase activity by membrane lipids. Biochemistry. 2004, 43: 14653-14666. 10.1021/bi048775y.View Article
- De Carolis E, Denis D, Riendeau D: Oxidative inactivation of human 5-lipoxygenase in phosphatidylcholine vesicles. Eur J Biochem. 1996, 235: 416-423. 10.1111/j.1432-1033.1996.00416.x.View Article
- Puustinen T, Scheffer MM, Samuelsson B: Endogenously generated 5-hydroperoxyeicosatetraenoic acid is the preferred substrate for human leukocyte leukotriene A4 synthase activity. FEBS Lett. 1987, 217: 265-268. 10.1016/0014-5793(87)80675-0.View Article
- Mogilevskaya E, Bagrova N, Plyusnina T, Gizzatkulov N, Metelkin E, Goryacheva E, Smirnov S, Kosinsky Y, Dorodnov A, Peskov K, Karelina T, Goryanin I, Demin O: Kinetic modeling as a tool to integrate multilevel dynamic experimental data. Methods Mol Biol. 2009, 563: 197-218. 10.1007/978-1-60761-175-2_11.View Article
- Kramer RM, Roberts EF, Manetta JV, Hyslop PA, Jakubowski JA: Thrombin-induced phosphorylation and activation of Ca(2+)-sensitive cytosolic phospholipase A2 in human platelets. J Biol Chem. 1993, 268: 26796-26804.
- Lukas TJ: A signal transduction pathway model prototype I: From agonist to cellular endpoint. Biophys J. 2004, 87: 1406-1416. 10.1529/biophysj.103.035253.View Article
- Smith CV, Jones DP, Guenthner TM, Lash LH, Lauterburg BH: Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol Appl Pharmacol. 1996, 140: 1-12. 10.1006/taap.1996.0191.View Article
- Bruynzeel PL, Kok PT, Viëtor RJ, Verhagen J: On the optimal conditions of LTC4 formation by human eosinophils in vitro. Prostaglandins Leukot Med. 1985, 20: 11-22. 10.1016/0262-1746(85)90090-3.View Article
- Linden M, Håkansson L, Ohlsson K, Sjödin K, Tegner H, Tunek A, Venge P: Glutathione in bronchoalveolar lavage fluid from smokers is related to humoral markers of inflammatory cell activity. Inflammation. 1989, 13: 651-658. 10.1007/BF00914309.View Article
- Graham FD, Erlemann KR, Gravel S, Rokach J, Powell WS: Oxidative stress-induced changes in pyridine nucleotides and chemoattractant 5-lipoxygenase products in aging neutrophils. Free Radic Biol Med. 2009, 47: 62-71. 10.1016/j.freeradbiomed.2009.04.016.View Article
- Sander BJ, Oelshlegel FJ, Brewer GJ: Quantitative analysis of pyridine nucleotides in red blood cells: a single-step extraction procedure. Anal Biochem. 1976, 71: 29-36. 10.1016/0003-2697(76)90006-3.View Article
- Hook R, Jeeves TA: Direct search solution of numerical and statistical problems. J ACM. 1961, 8: 212-229. 10.1145/321062.321069.View Article
- Gizzatkulov NM, Goryanin II, Metelkin EA, Mogilevskaya EA, Peskov KV, Demin OV: DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results. BMC Syst Biol. 2010, 4: 109-10.1186/1752-0509-4-109.View Article
- Rakonjac M, Fischer L, Provost P, Werz O, Steinhilber D, Samuelsson B, Rådmark O: Coactosin-like protein supports 5-lipoxygenase enzyme activity and up-regulates leukotrienee A4 production. Proc Nat Acad Sci USA. 2006, 103: 13150-13155. 10.1073/pnas.0605150103.View Article
- Percival D, Denis D, Riendeau D, Gresser MJ: Investigation of the mechanism of non-turnover-dependent inactivation of purified human 5-lipoxygenase. Eur J Biochem. 1992, 210: 109-117. 10.1111/j.1432-1033.1992.tb17397.x.View Article
- Jakobsson PJ, Mancini JA, Riendeau D, Ford-Hutchinson AW: Identification and characterization of a novel microsomal enzyme with glutathione-dependent transferase and peroxidase activities. J Biol Chem. 1997, 272 (36): 22934-9. 10.1074/jbc.272.36.22934.View Article
- Hatzelmann A, Schatz M, Ullrich V: Involvement of glutathione peroxidase activity in the stimulation of 5-lipoxygenase activity by glutathione-depleting agents in human polymorphonuclear leukocytes. Eur J Biochem. 1989, 180: 527-533. 10.1111/j.1432-1033.1989.tb14678.x.View Article
- Cakmak A, Zeyrek D, Atas A, Selek S, Erel O: Oxidative status and paraoxonase activity in children with asthma. Clin Invest Med. 2009, 32: E327-E334.
- Charnulitrat W, Mason RP, Riendeau D: Nitroxide metabolites from alkylhydroxylamines and N-hydroxyurea derivatives resulting from reductive inhibition of soybean lipoxygenase. J Biol Chem. 1992, 267: 9574-9579.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.